Stockscreener 앱 받기
38.80
1.57%
0.60
시간 외 거래:
38.80
전일 마감가:
$38.20
열려 있는:
$38.25
하루 거래량:
722.57K
Relative Volume:
1.00
시가총액:
$2.25B
수익:
$32.87M
순이익/손실:
$674.31M
주가수익비율:
3.4155
EPS:
11.36
순현금흐름:
$-330.11M
1주 성능:
+4.84%
1개월 성능:
-2.17%
6개월 성능:
+10.16%
1년 성능:
-15.10%
1일 변동 폭
$37.75
$39.69
1주일 범위
$35.92
$39.69
52주 변동 폭
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
명칭
Agios Pharmaceuticals Inc
전화
617-649-8600
주소
88 SIDNEY STREET, CAMBRIDGE, MA
AGIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
38.80 | 2.18B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 개시 | H.C. Wainwright | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-09-27 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 개시 | Piper Sandler | Overweight |
| 2022-11-17 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-03-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-02-15 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 개시 | Leerink Partners | Mkt Perform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-04-11 | 재확인 | Credit Suisse | Outperform |
| 2018-02-15 | 재확인 | Needham | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-10 | 재확인 | Needham | Buy |
| 2017-08-08 | 재확인 | SunTrust | Buy |
| 2017-08-02 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-01-17 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 개시 | Needham | Buy |
| 2016-06-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 재확인 | SunTrust | Buy |
모두보기
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
Can Agios Pharmaceuticals Inc. withstand a market correction2025 Sector Review & Consistent Growth Equity Picks - sundaytimes.kr
How to track smart money flows in Agios Pharmaceuticals Inc.Earnings Overview Report & Advanced Swing Trade Entry Plans - Newser
Will Agios Pharmaceuticals Inc. stock recover after recent dropMarket Performance Recap & Long-Term Safe Return Strategies - Newser
What makes Agios Pharmaceuticals Inc. stock price move sharplyJuly 2025 Movers & AI Optimized Trade Strategies - Newser
Can Agios Pharmaceuticals Inc. generate free cash flowCEO Change & Weekly Sector Rotation Insights - thegnnews.com
Published on: 2025-08-13 06:00:50 - Newser
How institutional ownership impacts Agios Pharmaceuticals Inc. stockJuly 2025 Action & Weekly High Potential Alerts - Newser
Can Agios Pharmaceuticals Inc. Regain Lost Ground This QuarterMarket Entry and Exit Point Tips From Traders - 선데이타임즈
Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors - Business Wire
Full technical analysis of Agios Pharmaceuticals Inc. stockLow Exposure Strategy with Sector Analysis - Newser
How Agios Pharmaceuticals Inc. stock performs during market volatilityMachine Learning Stock Price Forecast Tool - Newser
Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? - MSN
Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders - Yahoo Finance
Agios Pharmaceuticals Shares Plunge 23% Amid Safety Concerns - AInvest
TR | OpenAI4o Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Maintains Target Price $38 - 富途牛牛
Can a trend reversal in Agios Pharmaceuticals Inc. lead to recoveryChart Driven Entry Timing for Swing Trades - Newser
Agios Shares Fall 15% After Report of Deaths Among Pyrukynd Patients - MSN
TD Cowen reiterates Buy rating on Agios Pharma stock amid safety concerns - Investing.com Canada
Agios (AGIO) Q2 Revenue Jumps 45% - AOL.com
Agios: Patients’ deaths don’t alter Pyrukynd’s benefit-risk profile - BioWorld MedTech
Report of Patient Deaths Sends Agios Shares Seesawing - BioSpace
Agios falls as Leerink cites deaths linked to lead asset Pyrukynd - MSN
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating - 富途牛牛
Envestnet Asset Management Inc. Reduces Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $56 - 富途牛牛
SFDA approves Agios Pharma’s Pyrukynd for thalassemia - Yahoo Finance
Agios Retail Buzz Surges On Saudi Thalassemia Nod As Retail Hails ‘Incredible Recovery’ Despite FDA Concerns - Asianet Newsable
Agios Pharmaceuticals addresses analyst report on PYRUKYND safety data By Investing.com - Investing.com Nigeria
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia - The Manila Times
Breakthrough: Saudi Arabia Approves First-Ever Oral Treatment for All Adult Thalassemia Patients - Stock Titan
Chartists See Breakout Potential in Agios Pharmaceuticals Inc.Fast Exit and Entry Strategy Guide Offered - beatles.ru
Agios evaluating fourth Pyrukynd case after analyst report - TipRanks
Agios Pharma’s PYRUKYND Approved by Saudi Authority - TipRanks
Agios Pharmaceuticals addresses analyst report on PYRUKYND safety data - Investing.com
Agios Pharmaceuticals Becomes Oversold (AGIO) - Nasdaq
Agios Pharmaceuticals: Navigating Pyrukynd's Thalassemia PDUFA and Sickle Cell Pipeline Risks Amid Recent Valuation Pressure - AInvest
Agios stock falls on Pyrukynd-related deaths (AGIO:NASDAQ) - Seeking Alpha
Agios shares drop after report notes deaths of Pyrukynd patients By Investing.com - Investing.com Canada
How strong is Agios Pharmaceuticals Inc. company’s balance sheetBuild a winning investment portfolio - Jammu Links News
Agios Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding risk-reward balance - Jammu Links News
What analysts say about Agios Pharmaceuticals Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What is the risk reward ratio of investing in Agios Pharmaceuticals Inc. stockConsistent high-performance stocks - Jammu Links News
What are Agios Pharmaceuticals Inc. company’s key revenue driversCapitalize on fast-moving stock opportunities - Jammu Links News
What are the latest earnings results for Agios Pharmaceuticals Inc.Superior investment outcomes - Jammu Links News
When is Agios Pharmaceuticals Inc. stock expected to show significant growthAchieve rapid portfolio appreciation today - Jammu Links News
What is Agios Pharmaceuticals Inc. company’s growth strategyBuild wealth steadily with proven strategies - Jammu Links News
What are the technical indicators suggesting about Agios Pharmaceuticals Inc.Capitalize on market momentum for maximum gains - Jammu Links News
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates - MSN
Agios Pharmaceuticals Q2 2025: Unraveling Key Contradictions in Safety, Spending, and Pediatric Strategy - AInvest
Agios Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Agios expects modest full-year 2025 revenue growth with PYRUKYND thalassemia launch pending FDA approval - MSN
Agios Pharmaceuticals Inc (AGIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Agios Pharmaceuticals Inc 주식 (AGIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Smith Cynthia | Director |
Aug 11 '25 |
Option Exercise |
0.00 |
2,302 |
0 |
12,414 |
| Goff Brian | Chief Executive Officer |
Aug 08 '25 |
Option Exercise |
0.00 |
22,691 |
0 |
134,613 |
| Goff Brian | Chief Executive Officer |
Aug 08 '25 |
Sale |
36.67 |
11,085 |
406,487 |
123,528 |
0.94%
1.72%
자본화:
|
볼륨(24시간):